Guggenheim lowered the firm’s price target on 2seventy Bio to $26 from $27. Despite the lower guidance surprise, the firm keeps a Buy rating on the shares based on the Abecma opportunity and 2seventy’s below-cash valuation, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TSVT:
- 2seventy Bio reports Q2 EPS (83c), consensus ($1.15)
- TSVT Earnings this Week: How Will it Perform?
- 2seventy Bio price target lowered to $22 from $26 at Wedbush
- 2seventy Bio downgraded to Equal Weight from Overweight at Morgan Stanley
- 2seventy Bio price target lowered to $25 from $28 at Morgan Stanley